Condition: Long QT Syndrome (LQTS) 2 · Sponsor: Thryv Therapeutics, Inc.
The goal of this clinical trial is to learn whether the study drug THRV-1268 can safely and effectively shorten the QT interval in people diagnosed with Long QT Syndrome Type 2 (LQTS 2). The study will also learn about the safety and tolerability of THRV-1268 at different doses. The main questions this study aims to answer are: Does THRV-1268 reduce the QTc interval (a measure of the heart's electrical recovery time)? What side effects or medical problems occur when participants take THRV-1268? Which dose of THRV-1268 works best and is safest? Participants will: Complete a 3-week observation period with ECG and Holter monitoring to establish baseline QTc measurements Take THRV-1268 tablets twice daily at two dose levels for 6 weeks (Part A) or be randomly assigned to a dose group for 6 weeks (Part B) Have clinic visits and tests to monitor safety and changes in their heart rhythm May continue taking THRV-1268 for up to 1 year for ongoing safety and efficacy evaluation Researchers will compare changes in QTc over time and evaluate side effects to determine whether THRV-1268 can help reduce the risk of abnormal heart rhythms and sudden cardiac events in people with LQTS 2.
This description comes directly from the study's public registry record.
Study Director · 1-855-958-WAVE (9283) · waveiistudyteam@thryvtrx.com
Always discuss trial participation with your own doctor first.
| Honor Health Research and Innovation Institute | Scottsdale, Arizona, United States | Recruiting |
| University of California San Francisco | San Francisco, California, United States | Recruiting |
| University of Illinois Chicago | Chicago, Illinois, United States | Recruiting |
| Heart Center Clinical Research Program | MGH | Boston, Massachusetts, United States | Recruiting |
| University of Michigan | Arbor, Michigan, United States | Not Yet Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
| NYU Langone Health | New York, New York, United States | Not Yet Recruiting |
| Wilmington Health | Wilmington, North Carolina, United States | Recruiting |
| Oregon Health & Science University | Portland, Oregon, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07277582